Stem definition | Drug id | CAS RN |
---|---|---|
1585 | 6893-02-3 |
Dose | Unit | Route |
---|---|---|
60 | mcg | O |
60 | mcg | P |
Property | Value | Reference |
---|---|---|
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.00 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Hosey CM, Chan R, Benet LZ |
Date | Agency | Company | Orphan |
---|---|---|---|
May 8, 1956 | FDA | KING PHARMS R AND D |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Sensitisation | 214.79 | 14.17 | 53 | 10881 | 1529 | 50592661 |
Polycystic ovaries | 195.68 | 14.17 | 54 | 10880 | 2430 | 50591760 |
Ejection fraction | 172.02 | 14.17 | 42 | 10892 | 1158 | 50593032 |
Hypothyroidism | 152.99 | 14.17 | 94 | 10840 | 34031 | 50560159 |
Rhinitis allergic | 142.79 | 14.17 | 55 | 10879 | 7145 | 50587045 |
Sleep apnoea syndrome | 117.92 | 14.17 | 70 | 10864 | 23798 | 50570392 |
Blood test abnormal | 115.68 | 14.17 | 54 | 10880 | 11265 | 50582925 |
Carpal tunnel syndrome | 111.77 | 14.17 | 60 | 10874 | 16833 | 50577357 |
Sleep disorder due to a general medical condition | 103.70 | 14.17 | 44 | 10890 | 7327 | 50586863 |
Burning sensation | 89.55 | 14.17 | 76 | 10858 | 45370 | 50548820 |
Nephrectomy | 88.71 | 14.17 | 23 | 10911 | 812 | 50593378 |
Fibromyalgia | 76.13 | 14.17 | 69 | 10865 | 44909 | 50549281 |
Cardiac disorder | 74.84 | 14.17 | 67 | 10867 | 42912 | 50551278 |
Asthma | 60.51 | 14.17 | 85 | 10849 | 89252 | 50504938 |
Gastrooesophageal reflux disease | 56.69 | 14.17 | 76 | 10858 | 76352 | 50517838 |
Ejection fraction abnormal | 55.73 | 14.17 | 16 | 10918 | 831 | 50593359 |
Renal disorder | 50.10 | 14.17 | 44 | 10890 | 27461 | 50566729 |
Loss of personal independence in daily activities | 47.93 | 14.17 | 67 | 10867 | 69983 | 50524207 |
Therapeutic product effect incomplete | 40.95 | 14.17 | 72 | 10862 | 91443 | 50502747 |
Urine chloride decreased | 40.54 | 14.17 | 8 | 10926 | 78 | 50594112 |
Suicidal ideation | 36.43 | 14.17 | 52 | 10882 | 55333 | 50538857 |
Urine sodium decreased | 35.54 | 14.17 | 8 | 10926 | 153 | 50594037 |
Headache | 35.46 | 14.17 | 208 | 10726 | 506327 | 50087863 |
Myopathy | 33.03 | 14.17 | 22 | 10912 | 9117 | 50585073 |
Weight increased | 31.92 | 14.17 | 106 | 10828 | 201785 | 50392405 |
Hyperthyroidism | 31.71 | 14.17 | 24 | 10910 | 12151 | 50582039 |
Hypertension | 30.85 | 14.17 | 108 | 10826 | 211095 | 50383095 |
Product substitution issue | 28.67 | 14.17 | 24 | 10910 | 14033 | 50580157 |
Palpitations | 25.16 | 14.17 | 60 | 10874 | 94446 | 50499744 |
Thyroid function test abnormal | 22.49 | 14.17 | 12 | 10922 | 3320 | 50590870 |
Feeling abnormal | 21.71 | 14.17 | 68 | 10866 | 125424 | 50468766 |
Tri-iodothyronine increased | 20.90 | 14.17 | 5 | 10929 | 126 | 50594064 |
Blood thyroid stimulating hormone increased | 20.42 | 14.17 | 14 | 10920 | 6078 | 50588112 |
Acute kidney injury | 20.39 | 14.17 | 12 | 10922 | 228046 | 50366144 |
Blood thyroid stimulating hormone abnormal | 19.57 | 14.17 | 7 | 10927 | 738 | 50593452 |
Nail growth abnormal | 18.44 | 14.17 | 6 | 10928 | 475 | 50593715 |
Thyroid cancer | 17.43 | 14.17 | 11 | 10923 | 4158 | 50590032 |
Reaction to excipient | 16.55 | 14.17 | 7 | 10927 | 1155 | 50593035 |
Systemic lupus erythematosus | 16.39 | 14.17 | 5 | 10929 | 140617 | 50453573 |
Drug intolerance | 16.34 | 14.17 | 14 | 10920 | 219090 | 50375100 |
Pre-existing condition improved | 16.33 | 14.17 | 13 | 10921 | 7084 | 50587106 |
Product quality issue | 16.07 | 14.17 | 26 | 10908 | 30832 | 50563358 |
Tri-iodothyronine decreased | 15.96 | 14.17 | 4 | 10930 | 123 | 50594067 |
Scar | 15.92 | 14.17 | 16 | 10918 | 11802 | 50582388 |
Glossodynia | 15.64 | 14.17 | 3 | 10931 | 115566 | 50478624 |
Vascular injury | 15.00 | 14.17 | 6 | 10928 | 859 | 50593331 |
Blood thyroid stimulating hormone decreased | 14.97 | 14.17 | 10 | 10924 | 4162 | 50590028 |
Maternal exposure during pregnancy | 14.86 | 14.17 | 8 | 10926 | 159770 | 50434420 |
Arthropathy | 14.55 | 14.17 | 8 | 10926 | 157898 | 50436292 |
Product preparation error | 14.54 | 14.17 | 10 | 10924 | 4362 | 50589828 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Rhythm idioventricular | 48.88 | 25.16 | 9 | 1519 | 273 | 29572726 |
Secondary hypogonadism | 48.75 | 25.16 | 9 | 1519 | 277 | 29572722 |
Thyrotoxic periodic paralysis | 45.24 | 25.16 | 7 | 1521 | 71 | 29572928 |
Autoimmune thyroiditis | 42.39 | 25.16 | 10 | 1518 | 1026 | 29571973 |
Loose associations | 39.23 | 25.16 | 6 | 1522 | 56 | 29572943 |
Performance enhancing product use | 38.33 | 25.16 | 6 | 1522 | 66 | 29572933 |
Glucose tolerance decreased | 37.77 | 25.16 | 6 | 1522 | 73 | 29572926 |
Diffuse vasculitis | 37.70 | 25.16 | 6 | 1522 | 74 | 29572925 |
Sinus arrest | 34.22 | 25.16 | 9 | 1519 | 1438 | 29571561 |
Feelings of worthlessness | 30.48 | 25.16 | 6 | 1522 | 261 | 29572738 |
Haematocrit increased | 28.17 | 25.16 | 8 | 1520 | 1700 | 29571299 |
Hyperthyroidism | 28.03 | 25.16 | 12 | 1516 | 8596 | 29564403 |
Pressure of speech | 27.25 | 25.16 | 6 | 1522 | 452 | 29572547 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Sensitisation | 229.45 | 15.60 | 53 | 9594 | 1678 | 64487407 |
Polycystic ovaries | 223.02 | 15.60 | 54 | 9593 | 2101 | 64486984 |
Ejection fraction | 184.50 | 15.60 | 42 | 9605 | 1244 | 64487841 |
Rhinitis allergic | 152.54 | 15.60 | 54 | 9593 | 8024 | 64481061 |
Hypothyroidism | 143.34 | 15.60 | 84 | 9563 | 40373 | 64448712 |
Carpal tunnel syndrome | 133.26 | 15.60 | 59 | 9588 | 15769 | 64473316 |
Blood test abnormal | 121.18 | 15.60 | 52 | 9595 | 12891 | 64476194 |
Sleep disorder due to a general medical condition | 111.10 | 15.60 | 43 | 9604 | 8191 | 64480894 |
Fibromyalgia | 110.51 | 15.60 | 68 | 9579 | 35663 | 64453422 |
Sleep apnoea syndrome | 108.44 | 15.60 | 63 | 9584 | 29769 | 64459316 |
Burning sensation | 99.19 | 15.60 | 72 | 9575 | 49592 | 64439493 |
Nephrectomy | 84.96 | 15.60 | 23 | 9624 | 1399 | 64487686 |
Cardiac disorder | 78.98 | 15.60 | 66 | 9581 | 55750 | 64433335 |
Gastrooesophageal reflux disease | 72.41 | 15.60 | 75 | 9572 | 83068 | 64406017 |
Asthma | 62.37 | 15.60 | 74 | 9573 | 95151 | 64393934 |
Hyperthyroidism | 54.66 | 15.60 | 34 | 9613 | 18145 | 64470940 |
Loss of personal independence in daily activities | 51.94 | 15.60 | 59 | 9588 | 72395 | 64416690 |
Renal disorder | 50.38 | 15.60 | 42 | 9605 | 35323 | 64453762 |
Ejection fraction abnormal | 49.16 | 15.60 | 15 | 9632 | 1398 | 64487687 |
Therapeutic product effect incomplete | 46.79 | 15.60 | 67 | 9580 | 103415 | 64385670 |
Urine chloride decreased | 42.36 | 15.60 | 8 | 9639 | 91 | 64488994 |
Headache | 41.84 | 15.60 | 173 | 9474 | 529294 | 63959791 |
Hypertension | 37.60 | 15.60 | 104 | 9543 | 259157 | 64229928 |
Secondary hypogonadism | 37.18 | 15.60 | 9 | 9638 | 349 | 64488736 |
Thyrotoxic periodic paralysis | 35.99 | 15.60 | 7 | 9640 | 94 | 64488991 |
Urine sodium decreased | 34.18 | 15.60 | 8 | 9639 | 268 | 64488817 |
Rhythm idioventricular | 33.79 | 15.60 | 9 | 9638 | 514 | 64488571 |
Loose associations | 32.56 | 15.60 | 6 | 9641 | 59 | 64489026 |
Tri-iodothyronine increased | 31.61 | 15.60 | 7 | 9640 | 182 | 64488903 |
Glucose tolerance decreased | 31.17 | 15.60 | 6 | 9641 | 76 | 64489009 |
Performance enhancing product use | 30.68 | 15.60 | 6 | 9641 | 83 | 64489002 |
Diffuse vasculitis | 29.25 | 15.60 | 6 | 9641 | 107 | 64488978 |
Myopathy | 27.27 | 15.60 | 22 | 9625 | 17658 | 64471427 |
Insulin-like growth factor increased | 27.26 | 15.60 | 10 | 9637 | 1642 | 64487443 |
Suicidal ideation | 27.05 | 15.60 | 41 | 9606 | 66501 | 64422584 |
Blood thyroid stimulating hormone decreased | 24.33 | 15.60 | 13 | 9634 | 5217 | 64483868 |
Weight increased | 23.74 | 15.60 | 78 | 9569 | 213270 | 64275815 |
Feelings of worthlessness | 20.55 | 15.60 | 6 | 9641 | 480 | 64488605 |
Autoimmune thyroiditis | 19.95 | 15.60 | 10 | 9637 | 3518 | 64485567 |
Blood thyroid stimulating hormone increased | 19.74 | 15.60 | 13 | 9634 | 7641 | 64481444 |
Product substitution issue | 19.02 | 15.60 | 18 | 9629 | 17843 | 64471242 |
Thrombocytopenia | 19.01 | 15.60 | 5 | 9642 | 223796 | 64265289 |
Thyroid function test abnormal | 18.79 | 15.60 | 9 | 9638 | 2870 | 64486215 |
Product preparation error | 18.75 | 15.60 | 10 | 9637 | 3995 | 64485090 |
Feeling abnormal | 18.74 | 15.60 | 53 | 9594 | 133549 | 64355536 |
Drug withdrawal syndrome | 18.32 | 15.60 | 23 | 9624 | 31268 | 64457817 |
Palpitations | 18.26 | 15.60 | 45 | 9602 | 104443 | 64384642 |
Immunoglobulins decreased | 18.19 | 15.60 | 7 | 9640 | 1311 | 64487774 |
Sinus arrest | 18.19 | 15.60 | 9 | 9638 | 3081 | 64486004 |
Product dose omission issue | 17.18 | 15.60 | 66 | 9581 | 194681 | 64294404 |
Nail growth abnormal | 16.59 | 15.60 | 5 | 9642 | 447 | 64488638 |
Pressure of speech | 16.30 | 15.60 | 6 | 9641 | 995 | 64488090 |
None
Source | Code | Description |
---|---|---|
ATC | H03AA02 | SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS THYROID THERAPY THYROID PREPARATIONS Thyroid hormones |
ATC | H03AA03 | SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS THYROID THERAPY THYROID PREPARATIONS Thyroid hormones |
FDA CS | M0021977 | Triiodothyronine |
FDA EPC | N0000175946 | l-Triiodothyronine |
CHEBI has role | CHEBI:60311 | thyroid hormones |
CHEBI has role | CHEBI:75771 | Mus musculus metabolites |
CHEBI has role | CHEBI:77746 | Homo sapiens metabolite |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Goiter | indication | 3716002 | DOID:12176 |
Myxedema coma | indication | 21263006 | |
Hypothyroidism | indication | 40930008 | DOID:1459 |
Myxedema | indication | 43153006 | DOID:11634 |
Congenital hypothyroidism | indication | 190268003 | DOID:0050328 |
Simple goiter | indication | 267369002 | |
Malignant tumor of thyroid gland | indication | 363478007 | DOID:1781 |
T3 Suppression for Thyroid Function Test | indication | ||
Mild Hypothyroidism | indication | ||
Diagnostic Test for Thyroid Dysfunction | indication | ||
Myocardial infarction | contraindication | 22298006 | DOID:5844 |
Thyrotoxic crisis | contraindication | 29028009 | DOID:12837 |
Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
Conduction disorder of the heart | contraindication | 44808001 | |
Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
Osteoporosis | contraindication | 64859006 | DOID:11476 |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Hypopituitarism | contraindication | 74728003 | DOID:9406 |
Angina pectoris | contraindication | 194828000 | |
Osteopenia | contraindication | 312894000 | |
Primary adrenocortical insufficiency | contraindication | 373662000 | |
Disorder of coronary artery | contraindication | 414024009 |
Species | Use | Relation |
---|---|---|
Dogs | Hypothyroidism | Indication |
Product | Applicant | Ingredients |
---|---|---|
Cytobin Tablets | Zoetis Inc. | 1 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 2.08 | acidic |
pKa2 | 8.12 | acidic |
pKa3 | 8.77 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Thyroid hormone receptor alpha | Nuclear hormone receptor | AGONIST | Kd | 10.24 | CHEMBL | CHEMBL | |||
Thyroid hormone receptor beta | Nuclear hormone receptor | AGONIST | Ki | 10.10 | CHEMBL | CHEMBL | |||
Adenosine receptor A1 | GPCR | Ki | 6.62 | DRUG MATRIX | |||||
Cytochrome P450 2C9 | Enzyme | EC50 | 6.30 | WOMBAT-PK | |||||
Prothrombin | Enzyme | EC50 | 8.92 | CHEMBL | |||||
Peroxisome proliferator-activated receptor gamma | Nuclear hormone receptor | Kd | 6.15 | CHEMBL | |||||
Proliferating cell nuclear antigen | Nuclear other | IC50 | 5.44 | CHEMBL | |||||
THAP domain-containing protein 1 | Unclassified | EC50 | 9 | WOMBAT-PK | |||||
GABA-A receptor; anion channel | Ion channel | IC50 | 4.64 | CHEMBL | |||||
Thyroid hormone receptor beta | Transcription factor | IC50 | 8.74 | CHEMBL | |||||
GABA-A receptor; anion channel | Ion channel | EC50 | 5.15 | CHEMBL |
ID | Source |
---|---|
4022167 | VUID |
N0000020173 | NUI |
D01011 | KEGG_DRUG |
55-06-1 | SECONDARY_CAS_RN |
4018002 | VANDF |
4022167 | VANDF |
C0041014 | UMLSCUI |
CHEBI:18258 | CHEBI |
T3 | PDB_CHEM_ID |
CHEMBL1544 | ChEMBL_ID |
CHEMBL1201119 | ChEMBL_ID |
D014284 | MESH_DESCRIPTOR_UI |
DB00279 | DRUGBANK_ID |
2634 | IUPHAR_LIGAND_ID |
653 | INN_ID |
06LU7C9H1V | UNII |
5920 | PUBCHEM_CID |
10814 | RXNORM |
1964 | MMSL |
4982 | MMSL |
d00658 | MMSL |
002133 | NDDF |
004882 | NDDF |
126204001 | SNOMEDCT_US |
350358003 | SNOMEDCT_US |
61275002 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-2178 | TABLET | 25 ug | ORAL | ANDA | 26 sections |
Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-2179 | TABLET | 5 ug | ORAL | ANDA | 26 sections |
Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-2180 | TABLET | 50 ug | ORAL | ANDA | 26 sections |
Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-303 | TABLET | 50 1 | ORAL | ANDA | 13 sections |
Liothyronine sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-166 | TABLET | 5 ug | ORAL | ANDA | 24 sections |
Liothyronine sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-167 | TABLET | 25 ug | ORAL | ANDA | 24 sections |
Liothyronine sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-168 | TABLET | 50 ug | ORAL | ANDA | 24 sections |
Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33261-964 | TABLET | 5 ug | ORAL | ANDA | 25 sections |
Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 39822-0151 | INJECTION, SOLUTION | 10 ug | INTRAVENOUS | ANDA | 25 sections |
Triostat | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42023-120 | INJECTION | 10 ug | INTRAVENOUS | NDA | 25 sections |
NP Thyroid 15 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 42192-327 | TABLET | 2.25 ug | ORAL | unapproved drug other | 23 sections |
NP Thyroid 120 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 42192-328 | TABLET | 18 ug | ORAL | unapproved drug other | 22 sections |
NP Thyroid 30 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 42192-329 | TABLET | 4.50 ug | ORAL | unapproved drug other | 22 sections |
NP Thyroid 60 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 42192-330 | TABLET | 9 ug | ORAL | unapproved drug other | 22 sections |
NP Thyroid 90 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 42192-331 | TABLET | 13.50 ug | ORAL | unapproved drug other | 22 sections |
Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-417 | TABLET | 5 ug | ORAL | ANDA | 27 sections |
Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-418 | TABLET | 25 ug | ORAL | ANDA | 27 sections |
Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-419 | TABLET | 50 ug | ORAL | ANDA | 27 sections |
Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42794-018 | TABLET | 5 ug | ORAL | ANDA | 27 sections |
Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42794-019 | TABLET | 25 ug | ORAL | ANDA | 27 sections |
Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42794-020 | TABLET | 50 ug | ORAL | ANDA | 27 sections |
Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-884 | TABLET | 25 ug | ORAL | ANDA | 27 sections |
NP Thyroid 60 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 45865-566 | TABLET | 9 ug | ORAL | unapproved drug other | 22 sections |
Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-3131 | TABLET | 5 ug | ORAL | ANDA | 27 sections |
NP Thyroid 30 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50090-4376 | TABLET | 4.50 ug | ORAL | unapproved drug other | 22 sections |
NP Thyroid 60 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50090-5216 | TABLET | 9 ug | ORAL | unapproved drug other | 22 sections |
NP Thyroid 90 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50090-5229 | TABLET | 13.50 ug | ORAL | unapproved drug other | 22 sections |
Liothyronine sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-5586 | TABLET | 5 ug | ORAL | ANDA | 24 sections |
Liothyronine sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-5586 | TABLET | 5 ug | ORAL | ANDA | 24 sections |
Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-384 | TABLET | 5 ug | ORAL | ANDA | 27 sections |